Bluebird Ventures is an early-stage life sciences venture capital fund managed by Sutter Hill Ventures, founded in 2019 by Jeffrey Bird, MD, PhD. The firm creates and invests in life sciences companies with significant potential to impact the world.
67% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-a (47% of deals). Average disclosed round size is $83.7M (across 14 rounds with reported amounts).
Portfolio
10
Fund Size
—
Top Stage
Series A
Last 12 Mo
0
Team
JB
Jeff Bird
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
15 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Foresight Diagnostics | Series B | $58.8M | Apr 2023 |
 Leyden Labs | Series B | $140M | Jan 2022 |
| LLeyden Laboratories | Series B | $40M | Jan 2022 |
 Kriya Therapeutics | Series C | $270M | Jan 2022 |
| Foresight Diagnostics | Series A | $12.5M | Jun 2021 |
 Nutcracker Therapeutics | Series B | $60M | Sep 2020 |
| RRedPin Therapeutics | Series A | $15.5M | Mar 2020 |
 Epirium Bio | Series A | $85M | Dec 2019 |
 Epirium Bio | Series A | $85M | Jan 2019 |
| Epirium Bio | Series A | $85M | Jan 2019 |
| Kriya Therapeutics | Seed | — | — |
| Kriya Therapeutics | Series A | $80M | — |
| Kriya Therapeutics | Series B | $100M | — |
| NNutcracker | Series B | $60M | — |
 Kriya Therapeutics | Series A | $80M | — |
Top Co-Investors
ARCH Venture Partners5 shared
Foresite Capital4 shared
Longitude Capital3 shared
Adams Street Partners3 shared
Vertex Ventures HC3 shared
The Longevity Fund3 shared
Amplo3 shared
Narya3 shared
Alumni Ventures3 shared
Casdin Capital2 shared
F-Prime Capital2 shared
Gates Foundation2 shared
ClavystBio2 shared
Invest-NL2 shared
The Invus Group, LLC2 shared
Civilization Ventures2 shared
Pear VC2 shared
Cormorant Asset Management2 shared
GV1 shared
Last updated: 7 October 2026